Search: onr:"swepub:oai:DiVA.org:uu-150716" >
Achievement of reco...
-
Fernström, AndersÖstergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Njurmedicinska kliniken US,Njurmedicin
(author)
Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol : An observational study
- Article/chapterEnglish2011
Publisher, publication year, extent ...
-
2011-03-02
-
Informa UK Limited,2011
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-150716
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-150716URI
-
https://doi.org/10.3109/00365599.2011.553738DOI
-
https://lup.lub.lu.se/record/1926405URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:122202673URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-67150URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Objective. Secondary hyperparathyroidism (SHPT) is a common problem among patients with chronic kidney disease (CKD) on haemodialysis. This study was conducted to assess the use, effectiveness and safety of intravenous paricalcitol in haemodialysis patients with various degrees of SHPT. Material and methods. This observational, multicentre, prospective study was conducted in 14 Swedish dialysis centres from May 2007 to June 2008 and included 92 haemodialysis patients with a diagnosis of SHPT associated with CKD. The decision to initiate treatment with intravenous paricalcitol was made by the treating physician. No treatment algorithms were provided. Results. Mean patient age was 64 years. Of the 92 patients included, 74 had an intact parathyroid hormone (iPTH) level of > 300 pg/ml at baseline. Median iPTH was 584 pg/ml in patients with a baseline PTH of > 300 pg/ml. During follow-up there was a decrease in iPTH to 323 pg/ml at 6 months (--45%, p < 0.0001). In parallel, there was a small increase in serum calcium, but serum phosphorus and the calcium xx phosphorus product remained unchanged. Conclusions. This study showed that intravenous paricalcitol substantially and safely decreased iPTH in haemodialysis patients with a baseline iPTH above the Kidney Disease Outcomes Quality Initiative recommended target range (150--300 pg/ml) and had minimal impact on serum minerals.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Giaever, JanKarolinska University
(author)
-
Granroth, BarbaraSundsvall Hospital
(author)
-
Hylander, BrittaKarolinska Institutet,Karolinska University
(author)
-
Jensen, GertSahlgrenska University
(author)
-
Christensson, AndersLund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups,Malmo University Hospital(Swepub:lu)medf-ach
(author)
-
Wikström, BjörnUppsala universitet,Institutionen för medicinska vetenskaper,Akad University(Swepub:uu)bjorwiks
(author)
-
Weiss, LarsKarlstad Hospital
(author)
-
Wrege, UlfGavle Cent Hospital
(author)
-
Jacobson, Stefan H.Karolinska Institutet,Danderyd Hospital
(author)
-
Linköpings universitetHälsouniversitetet
(creator_code:org_t)
Related titles
-
In:Scandinavian Journal of Urology and Nephrology: Informa UK Limited45:3, s. 196-2050036-55991651-2065
Internet link
Find in a library
To the university's database
- By the author/editor
-
Fernström, Ander ...
-
Giaever, Jan
-
Granroth, Barbar ...
-
Hylander, Britta
-
Jensen, Gert
-
Christensson, An ...
-
show more...
-
Wikström, Björn
-
Weiss, Lars
-
Wrege, Ulf
-
Jacobson, Stefan ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Other Clinical M ...
- Articles in the publication
-
Scandinavian Jou ...
- By the university
-
Uppsala University
-
Lund University
-
Karolinska Institutet
-
Linköping University